MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Operating Cash Flow
Cash generated by the company's core business operations during the period.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $51.18M (cash outflow) rose 100.3% year over year, ahead of the +94.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at +73.2% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +100.3% holds above the trailing-twelve-month pace of +94.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (138.14M) USD
- Year-over-year change
- -75.3%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (138.14M) | -75.3% |
| FY2024 | 2024-12-31 | (78.82M) | -51.5% |
| FY2023 | 2023-12-31 | (52.01M) | -95.7% |
| FY2022 | 2022-12-31 | (26.58M) | — |
Operating Cash Flow vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 operating cash flow of $163.77M is the 4th largest of the 11 companies compared; the peer median is $56.97M.
- Its year-over-year change of +94.0% is the 2nd highest of 9, against a peer median of +14.9%.
- Over three fiscal years its annual growth of +73.2% compares with a peer median of +29.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.78B | — | +718.4% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $193.4M | -3.0% | +21.6% | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $190.28M | +67.0% | +37.9% | — |
| LTM Mar 2026 | $163.77M | +94.0% | +73.2% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $80.3M | +19.0% | +199.9% | 401.5% |
| LTM Mar 2026 | $62.3M | +17.6% | +36.4% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $51.63M | — | +134.6% | — |
| LTM Mar 2026 | $46.33M | +12.3% | +18.5% | — | |
| LTM Mar 2026 | $41.95M | -15.3% | -11.5% | 589.1% | |
| LTM Dec 2025 | $34.08M | -4.3% | +17.2% | — | |
| LTM Mar 2026 | $12.77M | +120.7% | -56.0% | 10.4% | |
| Peer median (excluding MPLT) | $56.97M | +14.9% | +29.0% | 401.5% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Other Non-Cash Items | 1.14M | 1.11M | 1.13M | 35.27M |
| Operating Cash Flow | (26.58M) | (52.01M) | (78.82M) | (138.14M) |
| Capital Expenditures | (746K) | (462K) | (770K) | (473K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (125.02M) | (408.23M) |
| Sales of Investments | 0 | 0 | 45M | 85.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (746K) | (462K) | (80.79M) | (323.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.17M | 104.57M | 120.25M | 474.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33.18M | 104.57M | (2.19M) | (5.02M) |
| Financing Cash Flow | 33.17M | 104.57M | 118.06M | 469.82M |
| Effect of Forex Changes | 21.81M | 0 | 27K | 0 |
| Net Change in Cash | 27.67M | 52.1M | (41.52M) | 8.48M |
| Free Cash Flow | (27.32M) | (52.47M) | (79.59M) | (138.61M) |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.